Share Market Newspaper

(Albany, US) On October 08, 2026 – DelveInsight’s, “Natural Killer Cell Therapies Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight’s comprehensive report today! @ https://www.delveinsight.com/sample-request/natural-killer-nk-cell-lymphoma-pipeline-insight

Key Takeaways from the Natural Killer Cell Lymphoma Pipeline Report

• On October 07, 2026 – GC Cell initiated a Phase Ib clinical trial of GCC2005, a fourth-generation allogeneic CD5-targeted CAR-NK cell therapy, and completed dosing of the first patient in patients with relapsed/refractory NK/T-cell lymphoma.
• · On October 07, 2026 – Atezolizumab demonstrated durable responses in patients with relapsed/refractory extranodal NK/T-cell lymphoma in the Phase II NCCH1903/ATTACK trial, with PD-L1-related biomarkers showing potential to predict treatment response.
• On October 07, 2026 – GC Cell initiated a Phase Ib clinical trial of GCC2005, a fourth-generation allogeneic CD5-targeted CAR-NK cell therapy, and completed dosing of the first patient in patients with relapsed/refractory NK/T-cell lymphoma.
• On October 06, 2026 – Peking University Cancer Hospital & Institute initiated a Phase II study evaluating a combination of dexamethasone, azacitidine, pegaspargase, and tislelizumab with radiotherapy in patients with Stage I/II extranodal NK/T-cell lymphoma, focusing on treatment efficacy and safety.
• DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma treatment.
• The leading Natural Killer (NK)-Cell Lymphoma Companies such as ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and Kuur Therapeutics (Formerly Cell Medica) and others.
• Promising Natural Killer (NK)-Cell Lymphoma Pipeline Therapies such as Velcade, Brincidofovir, AVM0703, Busulfan, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Natural Killer Cell Lymphoma Treatment Drugs

Natural Killer Cell Therapies Overview

Natural killer cells, also known as NK cells are a type of lymphocytes and are key components of the innate immune system. They are highly specific predators that play a major role in the host rejection of both tumors and viral infected cells. NK cell abnormalities have been observed in several cancer patients, including decreased cytotoxicity, defective expression of activating receptors or intracellular signaling molecules, overexpression of inhibitory receptors, defective proliferation, and decreased numbers in peripheral blood and tumor infiltrate, and defective cytokine production. NK cell therapy has been most successful in hematopoietic malignancies, such as leukemias. NK cell immunotherapy can be achieved by either activating endogenous NK cell response by administering NK stimulants or using exogenous NK cells via HSCT or adoptive cell transfer. Several strategies for NK cell immunotherapies for human cancer have been proposed to date. NK cell immunotherapy can be achieved in several ways

Natural Killer (NK)-Cell Lymphoma Emerging Drugs Profile

• Monalizumab: Innate Pharma

Monalizumab (also known as IPH2201) is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic NK and CD8 T lymphocytes. It is under development by Innate Pharma in Phase III stage for the treatment of Squamous Cell Carcinoma of the Head and Neck and in Phase II stage of development for the treatment of gynecological cancers, chronic lymphocytic leukemia, and head and neck cancer. It is in the Phase I stage of development for the treatment of advanced solid tumors and hematological malignancies.

• NKTR-214 (Bempegaldesleukin): Nektar Therapeutics

NKTR-214 is designed to grow specific cancer-killing T-cells and natural killer cell populations in the body that fight cancer is known as endogenous tumor-infiltering lymphocytes (TILs). NKTR-214 stimulates these cancer-killing immune cells in the body by targeting CD122 specific receptors found on the surface of these immune cells, known as CD8+ effector T cells and Natural Killer (NK) cells. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of these effector T cells.

• ALT 803: ImmunityBio

ALT 803 is a novel IL-15 superagonist complex, with improved pharmacokinetic properties and enhanced anti-tumor activity compared to recombinant human IL-15. It has also shown to potently activate human effector NK cells and enhance antibody-dependent cell-mediated cytotoxicity (ADCC) of anti-CD20 antibodies against human lymphoma cells in various tumor models. It is under development by Altor Bioscience Corporation and is currently in Phase II/III for Bladder Cancer. It is in Phase II stage for the treatment of Acute Myelogenous Leukemia (AML); Non-muscle Invasive Blood Cancer, in Phase I/II stage for the treatment of Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndromes (MDS); Multiple Myeloma; Advanced Pancreatic Cancer; Non-small Cell Lung Cancer and Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma. It is in Phase I stage for the treatment of Human Immunodeficiency virus (HIV) and Melanoma, Renal Cell, and Squamous Cell Head and Neck Cancer. It is developed by using IL-15 Protein Super agonist and Scaffold Technology and is administered by intravenous route.

• ALECSAT: CytoVac

ALECSAT (Autologous Lymphoid Effector Cells Specific against Tumor-cells) is a therapy that supplements and strengthens the patient’s immune system so it can fight the cancer cells in the same way as the body originally should have reacted. Natural Killer Cells used, in the ALECSAT therapy attack, the cancer cells in several ways, as they can recognize more than one property of the cancer cells. ALECAST is being evaluated for breast cancer and newly diagnosed glioblastoma in Phase II.

• PNK-007: Celularity

PNK-007 is a human umbilical cord blood-derived, culture-expanded natural killer cell therapy. The umbilical cord has CD34+ cells that are differentiated and expanded up to 50,000 fold over 35 days in a good manufacturing process (GMP) compliant facility to produce 12 billion cells that are 85% pure for NK cells without the use of a feeder cell line. These cells can be aliquoted and frozen for use at a later date. The CDK derived NK cells have substantial cytolytic activity against several human tumor cell lines, primary AML, and primary multiple myeloma cells. PNK-007 successfully completed pre-clinical studies for acute myeloid leukemia (AML) and multiple myeloma (MM) and is being evaluated in Phase I for the treatment of acute myeloid leukemia and Glioblastoma. PNK-007 is administered intravenously and developed by Cellular Therapeutics.

The Natural Killer (NK)-Cell Lymphoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Natural Killer (NK)-Cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Natural Killer (NK)-Cell Lymphoma Treatment.
• Natural Killer (NK)-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Natural Killer (NK)-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Natural Killer (NK)-Cell Lymphoma market

Explore groundbreaking therapies and clinical trials in the Natural Killer Cell Lymphoma Marketed and Pipeline Drugs @ New Natural Killer (NK)-Cell Lymphoma Drugs

Natural Killer (NK)-Cell Lymphoma Companies

ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and Kuur Therapeutics (Formerly Cell Medica) and others.

Natural Killer Cell Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intracranial
• Intramuscular
• Intratumoral
• Intravenous
• Intravenous
• Parenteral
• Subcutaneous
• Molecule Type

Natural Killer (NK)-Cell Lymphoma Products have been categorized under various Molecule types such as

• Small molecule
• Antibodies
• Beta Glucans
• CAR-NK cell therapy
• Cell Therapy
• Gene therapies
• Glycolipid
• NK Cell therapy
• NK T-Cell therapy
• Oligodeoxyribonucleotides
• Proteins
• RNA
• Stem cell therapies
• Vaccines
• Product Type

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Natural Killer Cell Lymphoma Market Drivers and Barriers

Scope of the Natural Killer (NK)-Cell Lymphoma Pipeline Report

• Coverage- Global
• Natural Killer (NK)-Cell Lymphoma Companies- ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmune GmbH, CytoVac, XNK Therapeutics, NantKwest, Green Cross Corporation, HiberCell, Bristol-Myers Squibb, Affimed Therapeutics AG, Wugen, Abivax, Glycostem Therapeutics (IPD Therapeutic), Synimmune, GT Biopharma, Bellicum Pharmaceuticals, Asclepius Technology Company Group, PersonGen BioTherapeutics (Suzhou), Chongqing Sidemu Biotechnology, Artiva Biotherapeutics, NKMax, Acepodia, Allife Medical Science and Technology, Bright Path Biotherapeutics, and Kuur Therapeutics (Formerly Cell Medica) and others.
• Natural Killer (NK)-Cell Lymphoma Pipeline Therapies- Velcade, Brincidofovir, AVM0703, Busulfan and others.
• Natural Killer (NK)-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Natural Killer (NK)-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Natural Killer Cell Lymphoma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Natural Killer Cell Therapies: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Natural Killer Cell Therapies – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Monalizumab: Innate Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ALECSAT: CytoVac
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CYAD-02: Celyad Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. CYT-501: Cytovia Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Natural Killer Cell Therapies Key Companies
21. Natural Killer Cell Therapies Key Products
22. Natural Killer Cell Therapies Unmet Needs
23. Natural Killer Cell Therapies Market Drivers and Barriers
24. Natural Killer Cell Therapies Future Perspectives and Conclusion
25. Natural Killer Cell Therapies Analyst Views
26. Natural Killer Cell Therapies Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-pipeline-insight